A share price of Kyverna Therapeutics Inc [KYTX] is currently trading at $2.21, down -7.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KYTX shares have gain 2.79% over the last week, with a monthly amount glided 5.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kyverna Therapeutics Inc [NASDAQ: KYTX] stock has seen the most recent analyst activity on October 10, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $13. Previously, Rodman & Renshaw started tracking the stock with Buy rating on October 09, 2024, and set its price target to $16. On July 03, 2024, H.C. Wainwright initiated with a Neutral rating and assigned a price target of $8 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $44 on March 04, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $40 as its price target on March 04, 2024. Leerink Partners started tracking with a Outperform rating for this stock on March 04, 2024, and assigned it a price target of $48. In a note dated March 04, 2024, JP Morgan initiated an Overweight rating and provided a target price of $39 on this stock.
Kyverna Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.78 and $16.64. Kyverna Therapeutics Inc [NASDAQ: KYTX] shares were valued at $2.21 at the most recent close of the market.
Analyzing the KYTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -0.52 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kyverna Therapeutics Inc [NASDAQ:KYTX] is 7.44. In addition, the Quick Ratio stands at 7.44 and the Cash Ratio stands at 1.71.
